NCT07533656Active, not recruiting
VAP-Measured Lipid Subfractions and In-Stent Restenosis After PCI
A Multicenter Observational Cohort Study of VAP-Measured Lipid and Lipoprotein Subfractions and In-Stent Restenosis After Percutaneous Coronary Intervention Across ASCVD Risk Strata
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
This multicenter observational study investigates whether lipid and lipoprotein subfractions measured by Vertical Auto Profile (VAP) are associated with coronary in-stent restenosis after percutaneous coronary intervention (PCI). The study includes a retrospective cross-sectional component in patients with prior PCI who undergo repeat coronary angiography and a prospective follow-up component in patients undergoing index PCI. Serum samples obtained from routine clinical blood collection will be used for VAP testing without additional blood draws.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 3600 (estimated)
- First submitted
- 30 Mar 2026
- Start date
- 1 Jul 2025
- Primary completion date
- 1 Jul 2028
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Diseases
- Coronary artery disease
- NCT number
- NCT07533656
What you commit to
- Study type: Observational
- Planned participants: 3600
- From 1 Jul 2025 to the primary completion date, 1 Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior CABG with angioplasty performed in a non-native vessel
Lab values
- Severe hepatic dysfunction (ALT or AST \>3 x ULN or Child-Pugh class C)
Other
- In-stent restenosis occurring within 1 month after PCI
- Expected survival \<1 year (prospective component)
Who the study is looking for
- Retrospective cross-sectional component:
- Age \>=18 years
- Prior successful implantation of second-generation drug-eluting stents
- Repeat coronary angiography available at a participating center
- Complete data available for ASCVD risk assessment
- Stored serum sample available for VAP testing
- Angiographic data sufficient to determine ISR status
- Prospective component:
- Age \>=18 years
- Undergoing index PCI
- Planned routine follow-up coronary angiography
- Complete data available for ASCVD risk assessment
- Serum sample available from routine clinical blood collection
- Able to provide written informed consent and any required privacy authorization
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Second Affiliated Hospital Zhejiang University School of Medicine Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.